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Abstract
Background: Genomic profiling of malignant tumours has assisted clinicians in providing targeted therapies for
many serious cancer-related illnesses. Although the characterisation of somatic mutations is the primary aim of
tumour profiling for treatment, germline mutations may also be detected given the heterogenous origin of
mutations observed in tumours. Guidance documents address the return of germline findings that have health
implications for patients and their genetic relations. However, the implications of discovering a potential but
unconfirmed germline finding from tumour profiling are yet to be fully explored. Moreover, as tumour profiling is
increasingly applied in oncology, robust ethical frameworks are required to encourage large-scale data sharing and
data aggregation linking molecular data to clinical outcomes, to further understand the role of genetics in
oncogenesis and to develop improved cancer therapies.
Results: This paper reports on the results of empirical research that is broadly aimed at developing an ethical
framework for obtaining informed consent to return results from tumour profiling tests and to share the
biomolecular data sourced from tumour tissues of cancer patients. Specifically, qualitative data were gathered from
36 semi-structured interviews with cancer patients and oncology clinicians at a cancer treatment centre in
Singapore. The interview data indicated that patients had a limited comprehension of cancer genetics and
implications of tumour testing. Furthermore, oncology clinicians stated that they lacked the time to provide in
depth explanations of the tumour profile tests. However, it was accepted from both patients and oncologist that
the return potential germline variants and the sharing of de-identified tumour profiling data nationally and
internationally should be discussed and provided as an option during the consent process.
Conclusions: Findings provide support for the return of tumour profiling results provided that they are
accompanied with an adequate explanation from qualified personnel. They also support the use of broad consent
regiments within an ethical framework that promotes trust and benefit sharing with stakeholders and provides
accountability and transparency in the storage and sharing of biomolecular data for research.
Keywords: Tumour profiling, Informed consent, Genomic data sharing, Germline mutations
Background
Advances in genomic technologies and declining costs
of sequencing have expanded opportunities to conduct
genetic profiling of diseased cells routinely. In oncology,
molecular testing of tumours, such as breast cancer, has
been practiced for over 20 years. These tests can define
the tumour subtype, which has important implications
for the selection of therapeutic options. However, testing
has since evolved to differentiate both heritable (germ-
line) and tumour-specific (somatic) mutations in tu-
mours. These developments have revolutionised cancer
care and bridged a new era of chemotherapy and tar-
geted treatments.
The value in delineating somatic and germline genom-
ics for therapeutic purposes has already been demon-
strated with the efficacy of ADP-ribose polymerase
(PARP) inhibitors for patients with a germline BRCA
* Correspondence: yasmin.bylstra@singhealth.com.sg
1POLARIS, Genome Institute of Singapore, Agency for Science, Technology
and Research, Singapore, Singapore
2SingHealth Duke-NUS Institute of Precision Medicine, Singapore, Singapore
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bylstra et al. Human Genomics  (2017) 11:31 
DOI 10.1186/s40246-017-0127-1
mutation [1]. In parallel, next generation sequencing
(NGS) platforms are also integral to translational cancer
research in identifying and validating promising new
biomarkers for the development of cancer treatment.
Worldwide collaborative efforts, such as The Cancer
Genome Atlas (TCGA) and the International Cancer
Genome Consortium (ICGC), have catalogued the gen-
omic landscapes of thousands of tumours. In such set-
tings, germline DNA has been routinely collected for
comparative analysis with tumour DNA from the same
patient to distinguish unambiguously true somatic muta-
tions from rare germline polymorphisms. However, clin-
ical practice is currently shifting towards a preference of
routinely sequencing a patient’s tumour tissue alone, to
characterise its molecular profile: reasons for this prefer-
ence include cost reduction and simplifying the logistics
of sample collection [2, 3]. Sequencing a patient’s
tumour tissue alone, in the absence of a matched germ-
line sample, challenges accurate delineation of somatic
versus germline mutations due to the heterogeneous na-
ture of mutations observed in tumours.
Until recently, there was no clear guidance on whether
or how findings that only imply germline variations from
genomic tumour profiling should be returned to pa-
tients. International governance bodies, such as the
World Health Organization (WHO) and the Organisa-
tion for Economic Co-Operation Development (OECD),
as well as national regulatory authorities around the
world, have issued guidelines on the management of
genetic databases; although few have developed explicit
guidance on the return of incidental findings [4]. These
guidance documents address the return of germline
findings known to have health implications for individ-
ual participants as well as their genetic relations. How-
ever, none address the situation where tumour profiles
results in a potential, but unconfirmed germline finding.
In response to the increasing utility of tumour-only test-
ing in clinical practice, the American Society of Clinical
Oncology (ASCO) updated their policy statement to in-
clude recommendations that the patients should be
made aware of the possible detection of germline muta-
tions [5]. However, the implications of these recommen-
dations in day-to-day clinical practice have not yet been
fully explored, particularly in Asia.
In addition to the uncertainty around managing inci-
dental findings, the need for sharing biomolecular data
internationally is increasingly being recognised as critical
to understanding the role of genetics in oncogenesis and
delivering more effective target therapies for cancer [6].
However, researchers require common guidelines to en-
sure accountability and ethical oversight for the protec-
tion of patient data that is shared between institutions
and across international borders [6, 7]. In 2014, the Glo-
bal Alliance for Genomics and Health (GA4GH)
published the Framework for Responsible Sharing of Gen-
omic and Health-Related Data that establishes a set of
foundational principles for sharing genomic and health-
related data [8]. According to this framework, best prac-
tices for sharing genomic and health-related data should
‘promote and protect respect for the commitment to
informed consent’ as the foundational principle that
underlies the ethical conduct of all research involving
human subjects [9]. However, while intended to facilitate
compliance with international norms, this framework
should also be interpreted in a manner that recognises
local cultural practices and the different contexts for
storing and sharing data.
In developing an ethical framework that is culturally
appropriate and sensitive to local norms, systems and
preferences, we initiated a qualitative study in Singapore
to explore the understandings, attitudes and preferences
that cancer patients and clinicians have towards the
return of results of tumour profiling tests as well as the
usage and sharing of the data for research purposes.
Singapore is an ethnically diverse and multi-cultured
country of 5 million situated in South East Asia. As most
published studies on patient understandings of genetic
testing have focused predominantly on Caucasian popu-
lations, there is value in gaining further insights from a
diverse Asian perspective. Currently, there are no laws
in Singapore to protect patients against employment and
insurance discrimination due to their genetic status. Any
framework for obtaining informed consent in this con-
text should also take into account local concerns about
genetic discrimination and trust in governance mecha-
nisms that oversee the storage and sharing of genome
data.
Methods
The study was designed with the aims of exploring and
describing the attitudes, understandings and preferences
that clinicians and cancer patients have towards partici-
pation in tumour profiling research, storage and sharing
of tumour genetic data, and the return of tumour profil-
ing results. To achieve these aims, the study design
employed qualitative research methods, which are useful
for documenting and explaining variation in a wide
range of views, needs, values, practices and beliefs [10].
These methods are not designed to estimate proportions
in a wider population, quantify relationships between
pre-determined variables or provide a single representa-
tive or average view or opinion [11]. However, they are
particularly useful for policy development and for the
design and delivery of health care and are especially
well-suited to exploring the understandings and attitudes
towards highly complex concepts and subjects that can-
not be fully captured with quantitative methodologies.
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Evidence for this study was collected from semi-
structured qualitative interviews with patients and clini-
cians at the National Cancer Centre Singapore (NCCS).
This method was chosen to provide a contextualised data-
set that focused on the specified issues and could generate
themes from clearly defined, homogeneous populations
within an already known context [10, 12]. Ethics approval
for this protocol was obtained from the Domain Specific
Research Board (DSRB) of SingHealth on 9 July 2015 to
conduct up to 40 semi-structured interviews with
SingHealth staff and cancer patients: (2015/2522).
Recruitment
Participants were selected using purposive sampling
techniques to allow for greater flexibility in targeting in-
formants and capture a broad range of perspectives [13]
until thematic saturation was reached (i.e. no new
themes were emerging from the data analysis to justify
continued recruitment) [14]. To identify relevant clini-
cians, clinical members of the research team provided a
list of 25 key oncologists at the NCCS. Three emails
were sent to these individuals over 3 weeks starting at
the end of July 2015. From these emails, six clinicians
agreed to be interviewed, resulting in a response rate of
24%. To increase the sample size, a second email invita-
tion was sent to an additional 59 SingHealth oncology
staff in early August. Of these, 15 responded and five
agreed to participate. This process resulted in a total of
11 participants being recruited from a pool of 74 con-
tacts (a response rate of 14.8%). No further attempts
were made to increase the sample size after the data
were thematically saturated at 11 interviews. These in-
terviews were conducted between July and September
2015 on the phone and face-to-face based on the prefer-
ences of participants.
For the patient group, eligible participants were re-
cruited from the waiting room at the NCCS with the as-
sistance of staff at the registration desk in the public
clinic as well as the nurses in the private clinic. Partici-
pants were offered a $50 supermarket voucher as fair
compensation for their time. Of the 28 patients
approached, only three declined to be interviewed result-
ing in a sample of 25 informants. The much higher re-
sponse rate of 89.3% in this group was likely due to the
support of their treating physician, being present onsite,
face-to-face recruitment and compensation. The patient
interviews were conducted in October 2015.
Interview protocol
An interview protocol for both groups was developed
from the issues identified in a literature review (see
Additional file 1). The clinician interviews were struc-
tured around three key issues to describe their attitudes
and preferences towards (1) how information on the
cancer diagnosis and the role of genetics (if any) is deliv-
ered to the patient; (2) delivery of the tumour profiling
test results; and (3) the type of informed consent docu-
ment needed to explain storing, sharing and withdrawal
of tumour profile data. The interview protocol for the
patient group was designed to explore participant atti-
tudes, understandings and preferences of key issues
including the purpose of the test; preferred linguistic
labels and options of delivering the informed consent;
the test procedures (sharing, storing and re-contact for
additional research); perceived benefits and risks; ideas
of altruism and solidarity; attitudes towards withdrawal
options; and role of family and medical professionals in
decision-making. The interview guide was piloted with
one patient in the colon cancer clinic before full data
collection proceeded.
Data analysis
All interviews were digitally recorded, transcribed verba-
tim and analysed using qualitative content analysis to
identify, categorise and interpret key themes in relation
to the consent process for storing and sharing of biomo-
lecular data. Transcripts were read multiple times by the
interviewer along with two study team members (YB
and TL) to identify major themes and sub-themes. These
themes and sub-themes were discussed together by the
three study team members to corroborate categories and
placement of relevant quotes. A coding frame was devel-
oped using these themes, which a fourth research ap-
plied to the data using NVivo© software (QSR
International). Reliability was checked with two of the
team members (YB and TL) independently coding pages
of randomly selected interview transcripts. Agreement
was measured using Cohen’s kappa coefficient [15].
Demographics (age, ethnicity, gender and type of cancer
diagnosis) were also collected for each patient and ana-
lysed using summative descriptive statistics (averages,
median and frequencies).
Results
From August to October 2015, 11 clinicians (7 oncolo-
gists, 2 cancer genetic specialists and 3 palliative care
doctors) were interviewed at the NCCS. Patients in both
the private and public breast cancer clinics were re-
cruited. In total, 25 patients were interviewed (see
Table 1 for demographic descriptions of patients).
The average age of those interviewed was 52, with a
median age of 54 years (ranging from 27 to 69). The ma-
jority were ethnic Chinese (10), with Indian (6) being the
next largest group. The process of obtaining informed
consent for the tumour profiling tests was discussed to
explore patient understandings of consent and their atti-
tudes towards the return of results and sharing of bio-
molecular data for research. From these discussions,
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broad themes emerged that described several issues con-
cerning participant understandings of cancer genetics
and tumour testing results, therapeutic misconceptions,
privacy and confidentiality. Results were supportive of a
broad consent model in these contexts.
Current practice for discussing tumour profiling tests
To frame the clinical context of discussions around
tumour profiling tests, the communication of this in-
formation was explored with both clinicians and pa-
tients. Clinicians indicated that their conversations
about tumour testing with their patients were heavily
simplified and that cancer genetics terms, such as
somatic and germline mutations, were not distin-
guished. Instead, information regarding the test was
briefly summarised by explaining that results would
clarify treatment options. Clinicians explained that
family history was raised if appropriate, or if patients
had any concerns, referrals would be made to the
cancer genetic clinics for further review.
‘And if you tell them that they have this mutation, it
means you can receive this drug. It will work on you
or not work on you. I think about, that is how we
explain it.’ (Clinician 1)
Likewise, patients also indicated that discussions around
genetics were limited, although some recalled being
asked about their family history of cancer. When ex-
plored further about the information needs the patients
desired, the response ranged widely. Some preferred
brief information whereas others wanted to be well-
informed. In discussions with patients about cancer gen-
etics and tumour profiling, it became apparent that they
had very limited understandings of these concepts and
many appeared confused about somatic and germline
genetics when raised. Cancer was generally perceived as
being primarily hereditary, even by one highly educated
patient who had a background in health
communications:
‘Generally as a lay person we are more inclined to look
at family genetics. We would not think about, what you
told me. When I say mutations, I was referring to the
family genes you mention to me…I know every cancer
cell is a mutation… normally when we talk about
mutations, we talk about family history.’ (Patient 9)
Clinicians interviewed also agreed that patients had lim-
ited understandings of genetics, mutations and cancer
development. Some suggested that these limitations
would even apply to clinicians who did not specialise in
cancer genetics:
‘It is does not stop at patients. Even physicians. I’ve
had so many…mis…even from physicians referring to
me you can understand that their grasp of it is very
low between driver and passenger mutations, between
actionable and not actionable. So you can’t blame
patients for not knowing this.’ (Clinician 11)
It emerged from both clinicians and patients that the
concepts around tumour profiling were complex and
would require in depth explanations for an appropriate
level of comprehension to be achieved.
Return of tumour profiling results
Current practices were explored regarding the return
tumour test results. Some clinicians gave their patients
the option of receiving the results as standard practice
and others believed that the results should be returned
to both the participant and their treating oncologist
without any opportunities for either party to opt out.
However, not all clinicians agreed with this approach, as
with many clinical tests, there can be uncertainty around
Table 1 Demographics of breast cancer patients interviewed
Patient ID Age Ethnicity No. of patients
1 43 Bangladeshi 2 (8%)
2 59 Bangladeshi










13 58 Filipino 1 (4%)






20 35 Malay 3 (12%)
21 63 Malay
22 68 Malay
23 27 Malay-Chinese 1 (4%)
24 50 Pakistani 1 (4%)
25 46 Vietnamese 1 (4%)
Total no. of patients 25
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the results and their implications for treatment. For ex-
ample, the pathogenicity of a variant may be unclear
(known as ‘variant of unknown significance’) or a variant
may be reported for research opportunities, such as clin-
ical trials, rather than for immediate clinical benefit.
‘…if you just give consent and say, “Here are the
clinical one and these are research ones”, and you just
say that, nothing else, no support about possible
uncertainty. And the patient comes back and says
“What does this mean?”, and the doctor says this
means “uncertainty”. And the patient says “Oh, this is
something you never told me, we [didn’t] know and I
don’t really want this.’ (Clinician 2)
As the tumour test panels can contain genes that are as-
sociated with hereditary conditions, there is the possibil-
ity that mutations in these genes derive from germline
origin and have familial implications. The prospect of
identifying germline incidental findings generated con-
flicting ideas amongst clinicians. Some clinicians dis-
cussed the possibility of discrimination that could follow
from germline analyses and suggested that more legal
protections, such as the Genetic Information Nondisclo-
sure Act (2008) in the USA, should be in place before
these types of tests are introduced widely into precision
oncology. Hence, there were stated preferences for
tumour profiling tests to exclude analysis of genes that
could imply germline mutations until measures were in
place. Others felt that patients should know, but should
be referred to another healthcare professional trained in
discussing germline implications:
‘I don’t think I can hide this from the patient. You
have to tell the patient. Patient’s interest for me to tell
them to get tested. This has implications for you. I
will send you to a trained cancer genetics oncologist
or counsellor or whatever to sort this out. It should
not be done in my clinic. It has to be someone
trained.’ (Clinician 10)
Most of the clinicians interviewed were clear about
their professional boundaries and limitations. They
understood that further evidence would be required
to support the origin of a germline finding and that
this was usually beyond their role as an oncologist.
They also agreed that they did not have sufficient
training to counsel and educate patients about germ-
line implications.
Patients, on the other hand, were clearer in their pref-
erences to receive their tumour profiling results. They
were informed that this information could include a risk
to hereditary conditions, such as breast cancer or cardiac
conditions, or new treatments currently under research.
Yet they were clear that they wanted to know about
these findings even if they had implications outside their
own cancer diagnosis. They indicated that they were
open to receiving any information that may help them
understand why they were diagnosed with cancer or ad-
vance their treatment:
‘I'm completely okay with that. So if there is a way
that we can receive then why not. We would like to
have the information.’ (Patient 21)
Many patients interviewed indicated a strong preference
to receive results with the provision that their oncologist
or another trusted healthcare professional explain the
implications of the results. They agreed that receiving
such information independent of any explanation could
create unnecessary confusion or worry. Therefore, if the
option of returning tumour tests is available to patients,
the inclusion and management of such incidental find-
ings must also be considered.
Data sharing
Significant to the advancements in research for new
therapies is the generation and accessibility of large and
diverse genomic data sets. The possibility of sharing the
genomic data obtained from the tumour tests with exter-
nal researchers, both locally and internationally, was dis-
cussed with clinicians and patients. Both groups
expressed the view that personal information had to be
delinked from the stored data before being shared with
third parties. Some clinicians also felt that the socio-
political culture in Singapore would mean that few pa-
tients would be overly concerned about the storage and
sharing of their results, and that they would likely con-
sent on the basis of assurances that their personal data
would be kept confidential in compliance with local laws
and regulations:
‘We in Singapore are not so worried about big brother
or privacy like you in the West. We are used to big
brother. We are a democracy, but have an overlay of
authoritarianism…we are used to having government
know about us and having access to our information.
Singaporeans will not be bothered about the storing
and sharing of data.’ (Clinician 6)
These cultural views were shared amongst some of the
patients interviewed who felt that there were sufficient
safeguards in Singapore to protect privacy and prevent
the data from being disclosed inappropriately and mis-
used, such as the Personal Data Protection Act (2012).
However, some patients were concerned about possible
misuses, particularly with respect to the potential for
discrimination:
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‘If it is only for the purpose of research it is okay.
There is no problem. But if for whatever reason my
name will be shown and published in a publically
available media, okay then basically I need to see it
and basically I need to have a positive consent for
myself before it is published.’ (Patient 6)
Some of the clinicians interviewed expressed concerns
about sharing patient data with research institutions in
other countries that lacked the accountability of publicly
funded institutions like in Singapore. It was also
expressed that sharing participant data for profit-
orientated research might create mistrust between on-
cologists and their patients if such information were re-
vealed at a later point. Such perceptions of ‘profit-
orientated’ institutions being driven towards the com-
mercial development of products for private benefit con-
flicted with views of genome research as a ‘public good’.
On the other hand, the patients interviewed did not
draw strong distinctions between public and private
goods, although the possibility of commercial products
being developed from shared tumour profile data was
not raised with these informants either. All patients
interviewed appeared to understand that they would not
benefit directly from the sharing of tumour profile data.
However, their willingness to allow their data to be
stored and shared with other institutions was sometimes
premised on an understanding that the research was
aimed at benefiting future cancer patients:
‘I feel very excited that someone can look at this and
figure it out. And if they can figure it out here or in
Argentina, I don’t really care. It is going to be helpful
to other people with a similar tumor profile I would
actually be very interested in donating my tumor to
science.’ (Patient 14)
There were also indications amongst clinicians that pa-
tients would agree to participate in research altruistically
if they believe it had the potential to benefit patients in
future as a societal good:
‘I think a lot of patients will do it for altruistic reasons..
most patients will do it. But I think they don’t want to
be made to feel as if they are guinea pigs. And so I
think that’s the balance you want to strike. I think you
might want to say “Look whatever profits we get from
these cell lines, we will donate it back to cancer”. They
don’t feel as if they are being taken for granted and they
are helping the future.’ (Clinician 9)
The reciprocation of indirect benefits back to the cancer
community would likely be a strong moral justification
for sharing tumour profile data. Most patients
interviewed in this study did not have a family history,
many wanted to understand why they had developed
cancer, and were trying to make sense of their diagnosis.
The possibility of having those questions answered
through increased knowledge of the causes and path-
ology of cancer was highly valued, and patients could
view themselves as contributing to that cause as a bene-
fit. Trust in the potential to generate further knowledge
around cancer causation may provide the strongest
moral justification for consenting to sharing data under
a broad consent regiment.
Broad consent as a model
Ensuring that patients understand test outcomes and
documenting preferences in both research and clinical
settings is conditional for informed consent. The process
of obtaining informed consent from patients to take part
in the tumour profiling tests was discussed with patients
and clinicians. These discussions centred on the length
and complexity of the consent form, the management of
test results and incidental findings, participation in re-
search and sharing of biomolecular data, the type of pre-
ferred consent and withdrawal options. In general, both
patients and clinicians preferred that information be
provided within a broad or blanket consent regiment
with an option to withdraw from the research.
Clinicians were generally familiar with the various
types of consent regiments (Table 2), and all but one
clinician felt that a blanket or broad consent would be
most appropriate in this setting. With respect the usage
of tumour profiling data for research, one clinician pre-
ferred a categorical consent out of concerns for sharing
genetic data outside cancer-related research. However,
most of the clinicians felt that documentation with mul-
tiple consent tiers would be confusing to patients and
cumbersome to manage:
“It would be more easier for scientists or researchers
to get the one that the patient already say “Okay, I
agree you can use it freely for research” and cover all
the parameters with the patient. It is easier for the
researcher. For the patient, they will feel “Why I have
to consent for so many things?” (Clinician 2)
Patients on the other hand were, at times, confused
about the concept of informed consent and the different
types of consent needed careful explaining. As discussed
above, although most patients preferred to receive any
potential incidental findings, this preference still needs
to be documented during the consent process.
As patients displayed a limited comprehension of
tumour testing and the clinicians expressed they had
limited time, additional support such as a dedicated
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coordinator or counsellor to explain the test in detail
and facilitate informed consent was suggested:
‘It may be better if someone else that is trained can
do it… you just need a trained counsellor or a trained
coordinator, research coordinator who is trained to
explain it. And then obviously, we have to take the
consent, we sort of don’t have to go through the
details of explaining. We just wrap up and answer any
specific questions or concerns.’ (Clinician 1)
While some clinicians agreed that a facilitator would be
helpful, in contrast others felt that the responsibility to
explain the results to participants should lie with the on-
cologist who has professional obligations to stay updated
on current evidence of best practice:
‘They can provide additional information to assist the
oncologists, but I think it is incumbent on the
individual oncologist to know the information.
Because at the end of the day they are physicians; it is
their responsibility to keep up to date. Genomics is so
much a part of oncology that you have to know.’
(Clinician 7)
While patients supported the assistance of a dedicated co-
ordinator or counsellor, there were some concerns about a
nurse being able to adequately answer questions, given the
perceived complexity of content in the consent form:
‘Definitely it's not the nurse; doctor should be fine, if
they have the time, looking at the patients. So I think
a neutral person before this test carried out. I think it
would be much better, so that they can understand.
But the words are pretty tough here for people to
understand.’ (Patient 16)
There was recognition from patients and clinicians that
support from an additional healthcare professional
would allow more time for questions, which may not
currently be possible in busy clinical settings. The costs
of appointing such a professional in a clinical context
were not explored with the informants, although the
findings suggest that the existing infrastructure would
not be well-equipped to absorb those costs.
Discussion
This paper reports on qualitative research with cancer
patients and oncology clinicians in Singapore to explore
current practices with tumour profiling tests and con-
sent preferences for the return of results and sharing of
their tumour profiling data. The results should be inter-
preted within the limitations of the study; notably, the
small sample size, low response rates from clinicians,
and restriction to breast cancer patients interviewed at a
single site in Singapore limits the generalisability of re-
sults to facilities outside of this context. However, the
aim of this study was not to produce generalizable find-
ings about patients and clinicians everywhere, but to ex-
plore and describe the perspectives, understandings and
attitudes of stakeholders who will likely engage and con-
tribute to the expansion of tumour profiling tests from
within the healthcare settings of Singapore. Thus, find-
ings are informative for obtaining consent in these con-
texts and may be relevant to other types of genome-
related research in Singapore and beyond. From the ana-
lysis, three major themes emerged: limited comprehen-
sion of cancer genetics and the consent process
indicating that decision support is required; the consent
preferences regarding the return of test results and usage
of tumour profiling data for research; and the issues of




Whereby consent is not explicitly sought from
participants to use their samples in research.
Blanket
consent
Consent that is sought from the participant once,
either at or prior to sample collection, for use in any




Consent that is sought from the participant once,
either at or prior to sample collection, for use in any
and all research without the need obtain further
consent from the participant, who then delegates
their decision making authority to an IRB (or another
institution) for specific research projects.
Categorical
consent
Consent that is sought from the participant to use
samples in particular categories of research, and may
include an option that allows researchers to recontact
participants for consent to use samples outside of
nominated areas of research.
Specific
consent
Consent that is sought from the participant to use
samples in specific research projects only, and may
include an option that allows researchers to recontact




Provision of multiple options for participants to
choose the type of consent they wish to provide.
Types of consent methods
Opt out Whereby consent is not explicitly sought for a given
action, but participants are informed about the
option to withdraw.
Opt in Whereby verbal or written consent is explicitly sought
from the participant to use samples in research.
Types of withdrawal options
Tiered
withdrawal
Whereby participants are given numerous options to
withdraw in varying degrees. I.e. to withdraw from
further contact while leaving samples and data in the
study, or withdraw samples while leaving data, or
withdraw all samples, personal information and
discontinued use of data
Single
withdrawal
Whereby participants are given the option to either
continue participation or withdraw completely.
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trust and accountability in relation to research involve-
ment. These findings are discussed in further detail
below.
Decision support for obtaining consent
One significant finding that emerged from the data was
the limited comprehension that patients may have of
cancer genetics and implications of the tumour profiling
results. It was also evident confusion arose around the
concept of consent and preferences to obtaining con-
sent. These findings are not limited to Singapore, as pre-
viously reported evidence is suggestive of limited
comprehension amongst participants in genome re-
search of genomics and cancer genetics [16–19]. In
addition, comprehension limits can also be complicated
by the multi-lingual context and cultural beliefs within
local healthcare settings that may contribute to the var-
ied understandings of genes and inheritance in cancer
development [20]. Although cancer healthcare profes-
sionals interviewed were aware of the possibility tumour
testing panels contained genes associated with hereditary
conditions, there was no indication that this was dis-
cussed with their patients. In fact, if there were any indi-
cations of hereditary implications, clinicians made
referrals to inherited cancer services.
Recently, recommendations from both ASCO and Na-
tional Comprehensive Cancer Network (NCCN) support
the view that patients should be informed about the po-
tential of tumour profiling results inferring hereditary
conditions, as well as the potential benefits, limitations
and risks prior to the test taking place [5, 21]. Clinicians
stated that they often lacked the time to explain medical
protocols and outcomes in detail with their patients, and
indicated that would they would not have time to pro-
vide lengthy explanations of the tumour profile tests.
This reality of the local healthcare setting suggests that
additional resources would be required to support the
consent process. In research settings, dedicated co-
ordinators are frequently appointed to support the re-
cruitment and consent process. In the context of gen-
omic research, some scholars have recommended the
appointment of trained genetic counsellors to deliver the
consent documentation and explain to participants the
implications of consenting as they are trained to discuss
issues related to germline genetic tests [17, 22].
With the significance of tumour profiling panels con-
taining genes associated with hereditary risk, it has been
proposed that the role of a genetic counsellor to deliver
counselling around such tests should become more pre-
dominant in oncology as consultations parallel germline
testing [21]. In countries where genetic counselling ser-
vices are limited, such as Singapore, the involvement of
a trained co-ordinator was proposed. With a few excep-
tions, the clinicians were generally supportive of a
dedicated clinical co-ordinator or researcher being avail-
able to explain the consent documentation in detail and
take the written consent from participants. The add-
itional support to assist with consent will require fund-
ing to compensate for the cost of this service. This
responsibility may extend to the role of existing hospital
employees to assist with the consent or this service
could be included in the cost of the tumour profiling
test. Institutions will need to consider how the cost of
such support can be absorbed.
Consent preferences for returning results and data
sharing
Recommendations provided by the ASCO and NCCN
also emphasise that patients should be given the oppor-
tunity to opt out of receiving possible incidental germ-
line findings. In addition, for those patients interested
learning more about germline origin should be further
investigated for their pathogenicity [5, 21]. The obliga-
tion to return research results and incidental findings to
patients in genetics research is contested and currently
lacks consensus [4]. In Singapore, there are currently no
laws that create legal duties for clinicians or researchers
to return results or incidental findings to participants;
nor are there any explicit rights ‘not to know’. As rec-
ommended, results from this study also suggest that par-
ticipants should be given the option to receive the
results of their tumour profiling test, and be made aware
of the potential for incidental findings during the con-
sent process.
However, discussions became more complex regarding
how incidental findings should be highlighted if patients
opted to receive a copy of their tumour profiling results.
While one clinician interviewed suggested the removal
of those genes with germline implications from the
tumour test report, most clinicians and patients were
generally comfortable with the inclusion of these genes
providing that they were accompanied with an adequate
explanation. In recommendations for the delivery of
tumour profiling results, it has been suggested that on-
cologists draw on the expertise of genetics specialists to
assist with the interpretation and discussions of those
findings with participants [21, 23]. The possibility of in-
cidental germline findings and genetic discrimination
also emerged from interview data. As there are currently
no laws in Singapore to protect patients against employ-
ment and insurance discrimination due to their genetic
status this approach also justifies a role for genetics spe-
cialists having a role to raise awareness of such issues.
Therefore, the possibility of incidental findings being re-
vealed with the return of tumour profiling results should
be acknowledged along with ensuring that participants
are referred to relevant specialists to validate the find-
ings and take action where appropriate.
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There are currently no guidelines or recommendations
on how these preferences towards the return of results
should be captured. It is also apparent from literature
that the consent framework and clinical processes to in-
form patients and document preferences about the her-
editary implications of tumour profiling tests remain
uncertain. Results from the present study suggest that
clinicians and cancer patients would prefer a simple
model where consent is given just once. This model was
preferred by clinicians because they lacked the time
needed to explain adequately the implications of mul-
tiple consent options. Some also felt that participants
would not fully comprehend different categories of re-
search and would be happy to provide a one-off consent.
They also specified that if testing revealed information
beyond somatic implications that this should be cap-
tured separately, by including a tick box, to consenting
for tumour profiling to be performed.
This view also extended to preferences around the
usage of tumour profiling data for research applications.
Patients were generally unconcerned about the provision
of their data providing it was shared with external re-
searchers in a de-identified format, and in compliance
with Singapore laws and regulations. Similar to the many
other studies published previously, the findings indicated
support for a broad consent model that delegates
decision-making authority to an independent oversight
body, such as an ethics review committee or institutional
review board [24, 25].
Trust and governance
From the results of this study, it is clear that the storage
and sharing of tumour profiling data cannot be ethically
justified as merely an exercise of personal autonomy
when the informed consent of participants is inherently
limited. Even with the support of dedicated research staff
and a simplified consent process, the degree to which
cancer patients can be truly informed of the implications
for consenting to the storage and sharing of these data
with researchers in Singapore and abroad is uncertain.
Thus, it is important to ensure that other measures are
in place to protect participants from unnecessary harms
and that their data is shared within the morally accepted
parameters of the consent. In short, participants must be
able to trust that their data will be protected and used
for the purposes they consented to.
A lack of trust with clinicians and patients would have
significant implications for the value of biomolecular
databanks specific to the health needs of the Singapor-
ean population. Storage and sharing these data with ex-
ternal researchers will be key to fostering research and
ensuring the widest public health benefits [6]. The po-
tential for these benefits justifies the enormous public
resources that are invested in genomic databanks and
their purpose as a public good. Maintaining trust in this
public good not only requires security measures to pro-
tect the data of participants, but will also require trans-
parency in how the data are accessed and how social
and economic benefits are distributed [26]. Any
intention to privatise these benefits should be disclosed
to participants prior to consenting and policies should
be in place to restrict access to the data for purposes
participants have consented to.
The results of this study support the adoption of a
broad consent model where participants would not con-
sent to specific projects or types of research. However,
they also suggest that participants would consent altruis-
tically on the condition that their data is used for re-
search that has the potential to benefit other cancer
patients in the future. This finding is supported in the
literature with other evidence that solidarity with future
patients incentivises participation in research that is un-
likely to have direct benefits for participants [27]. The
solidarity principle forms the basis of ethical arguments
that justify the use of broad consent regiments for gen-
omic research [28] and is strongly advocated by the
HUGO Committee on Ethics, Law and Society [29]. Yet,
the acceptability of this approach is also attached with
provisions for governance mechanisms that ensure
transparency and accountability in how data are stored
and shared with other researchers and institutions. Such
mechanisms may include approval from an ethics review
committee for specific projects, or a separate independ-
ent body comprised of members with relevant expertise
to provide oversight for the release of data to external
institutions and the distribution of benefits [7].
While the results of this study indicate that partici-
pants would consent to tumour profiling data being
shared for the purposes of cancer research, this might
not be limited to cancer research only as other types of
biomedical research were not discussed in the inter-
views. However, the consent might not extend to non-
medical related research, such as military research or fo-
rensic investigations. Concerns over the use of genetic
data for these purposes has been raised in the literature
[30, 31], and while they are most relevant to germline
research rather than somatic tumour profiling, partici-
pants are unlikely to understand these differences well
enough to assume that they appreciate the risks of shar-
ing these data. In these circumstances, institutions must
assume a guardianship role to ensure that the data
entrusted to them is not misused or perceived as such.
Finally, the concept of benefit sharing is another
principle that has emerged to justify the use of broad
consent regiments for genomic research [28] and is also
endorsed by HUGO [32] Committee on Ethics, Law and
Society. This principle does not imply that participants
should benefit directly, as it is important not to promote
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therapeutic misconception. Rather, the principle priori-
tises benefits to be shared with communities. In the
context of this study, the principle implies that mecha-
nisms should be in place for the expedient dissemination
of published research results as new discoveries in
cancer treatments emerge and the reclassification of
variants becomes clinically significant.
Conclusions
As the integration of NGS to inform patient care is
continually evolving in oncology practice, this is experi-
ence is novel to clinicians, researchers and especially to
patients. Therefore, developing a framework for obtain-
ing consent from participants for this type of testing
becomes challenging when recommendations specific to
tumour profiling worldwide are only emerging and there
are no best practice principles explicit to genomic test-
ing in a Singaporean context.
This study has highlighted that there is limited public
awareness around cancer causation and genetics as well
as an understanding of what informed consent entails.
As genomics advances, communication of these con-
cepts will become increasingly complicated, yet highly
relevant to ensure realistic expectations of the test out-
comes. It has become evident that support is required
when tumour profiling tests are offered, from either a
clinic co-ordinator or genetic counsellor, so that infor-
mation and test outcomes are explained, ultimately
ensuring that informed consent can be obtained in
precision oncology settings.
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